JP2024510930A - トレプロスチニル及びそのプロドラッグの乾燥粉末組成物、及び、さらに（ｅ）－３，６－ビス［４－（ｎ－カルボニル－２－プロペニル）アミドブチル］－２，５－ジケトピペラジン（ｆｄｋｐ）を含む乾燥粉末組成物 - Google Patents

トレプロスチニル及びそのプロドラッグの乾燥粉末組成物、及び、さらに（ｅ）－３，６－ビス［４－（ｎ－カルボニル－２－プロペニル）アミドブチル］－２，５－ジケトピペラジン（ｆｄｋｐ）を含む乾燥粉末組成物 Download PDF

Info

Publication number
JP2024510930A
JP2024510930A JP2023553046A JP2023553046A JP2024510930A JP 2024510930 A JP2024510930 A JP 2024510930A JP 2023553046 A JP2023553046 A JP 2023553046A JP 2023553046 A JP2023553046 A JP 2023553046A JP 2024510930 A JP2024510930 A JP 2024510930A
Authority
JP
Japan
Prior art keywords
substituted
treprostinil
treprostinyl
salt
dry powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023553046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510930A5 (cg-RX-API-DMAC10.html
Inventor
バトラ ヒテシュ
クオ リャン
ポアソン パトリック
ジャナ サソバン
Original Assignee
ユナイテッド セラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユナイテッド セラピューティクス コーポレイション filed Critical ユナイテッド セラピューティクス コーポレイション
Publication of JP2024510930A publication Critical patent/JP2024510930A/ja
Publication of JP2024510930A5 publication Critical patent/JP2024510930A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023553046A 2021-03-03 2022-03-02 トレプロスチニル及びそのプロドラッグの乾燥粉末組成物、及び、さらに（ｅ）－３，６－ビス［４－（ｎ－カルボニル－２－プロペニル）アミドブチル］－２，５－ジケトピペラジン（ｆｄｋｐ）を含む乾燥粉末組成物 Pending JP2024510930A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156110P 2021-03-03 2021-03-03
US63/156,110 2021-03-03
PCT/US2022/018505 WO2022187352A1 (en) 2021-03-03 2022-03-02 A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)

Publications (2)

Publication Number Publication Date
JP2024510930A true JP2024510930A (ja) 2024-03-12
JP2024510930A5 JP2024510930A5 (cg-RX-API-DMAC10.html) 2025-03-11

Family

ID=80930276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023553046A Pending JP2024510930A (ja) 2021-03-03 2022-03-02 トレプロスチニル及びそのプロドラッグの乾燥粉末組成物、及び、さらに（ｅ）－３，６－ビス［４－（ｎ－カルボニル－２－プロペニル）アミドブチル］－２，５－ジケトピペラジン（ｆｄｋｐ）を含む乾燥粉末組成物

Country Status (9)

Country Link
US (2) US12168071B2 (cg-RX-API-DMAC10.html)
EP (1) EP4301372A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024510930A (cg-RX-API-DMAC10.html)
KR (1) KR20240012354A (cg-RX-API-DMAC10.html)
CN (1) CN117479946A (cg-RX-API-DMAC10.html)
AU (1) AU2022229367A1 (cg-RX-API-DMAC10.html)
CA (1) CA3209987A1 (cg-RX-API-DMAC10.html)
IL (1) IL305510A (cg-RX-API-DMAC10.html)
WO (1) WO2022187352A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119632930A (zh) 2019-04-29 2025-03-18 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
CN121241041A (zh) * 2023-01-19 2025-12-30 联合治疗公司 曲前列尼尔类似物及相关制备和使用方法
EP4680223A1 (en) * 2023-03-17 2026-01-21 Insmed Incorporated Spray dried treprostinil formulation
WO2025174856A1 (en) * 2024-02-12 2025-08-21 Mannkind Corporation Process for making a composition for pulmonary inhalation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504684A (ja) * 2016-01-29 2019-02-21 マンカインド コーポレイション 乾燥粉末吸入器
WO2019237028A1 (en) * 2018-06-07 2019-12-12 Mannkind Corporation Composition and method for inhalation

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2485614A (en) 1946-08-29 1949-10-25 Chicago Bridge & Iron Co Stabilizing and guide apparatus for lifter roofs
US3037116A (en) 1957-07-26 1962-05-29 Weber Georges Apparatus for irradiating liquids
US3035516A (en) 1958-08-18 1962-05-22 Lee Brothers Company Stencil device
US3646509A (en) 1969-08-08 1972-02-29 Texas Instruments Inc Method for field stacking seismic data and system using write after read bulk data storage
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
US4547016A (en) 1984-08-13 1985-10-15 Eeco Incorporated Quick release mounting
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
IT1231076B (it) 1989-09-28 1991-11-12 Pirelli Cavi Spa Procedimento per la realizzazione di gruppo di connessione separabile per fibre ottiche riunite a nastro e gruppo di connessione con esso realizzato.
GB9011588D0 (en) 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
ES2214753T3 (es) 1997-11-14 2004-09-16 United Therapeutics Corporation Uso de 9-desoxi-2',9-alfa-metano-3-oxa-4,5,6-trinor-3,7-(1',3'-interfenilen)-13,14-dihidro-prostaglandina f1 para tratar la enfermedad vascular periferica.
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
KR20020012169A (ko) 1999-03-31 2002-02-15 유나이티드 쎄러퓨틱스 코포레이션 프로스타글란딘 화합물, 조성물 및 말초혈관질병 및폐고혈압증의 치료방법
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
US6700025B2 (en) 2001-01-05 2004-03-02 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6803386B2 (en) 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
US6756117B1 (en) 2002-12-20 2004-06-29 The United States Of America As Represented By The United States Department Of Energy Photonic polymer-blend structures and method for making
CN102697790A (zh) 2003-05-22 2012-10-03 联合治疗公司 化合物和释放前列环素类似物的方法
US20090124697A1 (en) 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
US7199157B2 (en) 2003-12-16 2007-04-03 United Therapeutics Corporation Use of treprostinil to improve kidney functions
CN1917866B (zh) 2003-12-16 2010-12-15 联合治疗公司 曲前列环素或它的衍生物，或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途
DE602005020269D1 (de) 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
CA2654492C (en) 2006-05-15 2017-06-27 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
US20090036465A1 (en) 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
CA2678258A1 (en) 2007-02-09 2008-08-14 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
CN103181893A (zh) 2007-09-07 2013-07-03 联合治疗公司 针对革兰氏阴性细菌具有选择性杀菌活性的缓冲液及其使用方法
WO2009078965A1 (en) 2007-12-17 2009-06-25 United Therapeutics Corporation An improved process to prepare treprostinil, the active ingredient in remodulin
JP6219016B2 (ja) 2008-05-08 2017-10-25 ユナイテッド セラピューティクス コーポレーション トレプロスチニル一水和物
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
CN102421288B (zh) 2009-05-07 2015-04-22 联合治疗公司 前列环素类似物的固体剂型
AU2010280684B2 (en) 2009-08-07 2016-07-28 Scipharm Sarl Composition for the treatment of cystic fibrosis
KR20160132501A (ko) 2010-03-15 2016-11-18 유나이티드 세러퓨틱스 코오포레이션 폐고혈압의 치료
CN103261142B (zh) 2010-06-03 2014-12-10 联合治疗公司 曲前列环素的制备
CA2710725C (en) 2010-07-22 2017-08-01 Alphora Research Inc. Protected aldehydes for use as intermediates in chemical syntheses, and processes for their preparation
CA2710726C (en) 2010-07-22 2016-02-23 Alphora Research Inc. Synthesis of treprostinil and intermediates useful therein
CA2726599C (en) 2010-12-30 2017-07-25 Alphora Research Inc. Process for treprostinil salt preparation
ES2581762T3 (es) 2011-03-02 2016-09-07 United Therapeutics Corporation Síntesis de producto intermedio para la producción de treprostinil
US9388154B2 (en) 2011-09-12 2016-07-12 Lund Biotechnology PBC Process for preparing synthetic prostacyclins
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
US9387214B2 (en) 2012-01-13 2016-07-12 United Therapeutics Corporation Method of identifying therapies for pulmonary hypertension
SI2674413T1 (sl) 2012-06-15 2017-10-30 Scipharm Sarl Postopek za pripravo treprostinila in derivatov le-tega
WO2014085813A1 (en) 2012-11-30 2014-06-05 Insmed Incorporated Prostacylin compositions and methods for using the same
CN104837806A (zh) 2012-12-07 2015-08-12 开曼化学股份有限公司 前列环素类似物的合成方法
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
WO2014159050A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
EP2970081A4 (en) 2013-03-15 2016-10-12 United Therapeutics Corp SALTS OF TREPROSTINIL
CA2911172C (en) 2013-04-30 2021-10-19 United Therapeutics Corporation Controlled release pharmaceutical formulations
WO2014203278A2 (en) * 2013-06-19 2014-12-24 Msn Laboratories Private Limited NOVEL PROCESS FOR THE PREPARATION OF (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-HEXAHYDRO-2-HYDROXY-1-[(3S)-3-HYDROXYOCTYL]-1H-BENZ[f]INDEN-5-YL]OXY]ACETIC ACID
US9469600B2 (en) 2013-10-25 2016-10-18 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
JP2016538161A (ja) 2013-11-27 2016-12-08 コーニング インコーポレイテッド 基板の改善された製造のための組成
TWI685348B (zh) 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
WO2015174197A1 (ja) 2014-05-14 2015-11-19 富士電機株式会社 半導体装置および半導体装置の製造方法
ES2908142T3 (es) 2014-06-13 2022-04-27 United Therapeutics Corp Formulaciones de treprostinil
US20160045470A1 (en) 2014-08-12 2016-02-18 Dr. Reddy's Laboratories Limited Amorphous solid dispersion of treprostinil diethanolamine
WO2016038532A1 (en) 2014-09-09 2016-03-17 Mylan Laboratories Limited Amorphous treprostinil diethanolamine
HU231184B1 (hu) 2014-10-08 2021-07-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Treprostinil-nátrium-monohidrát és eljárás ennek előállítására
CN107108427A (zh) 2014-10-20 2017-08-29 联合治疗学有限公司 用于制备前列环素衍生物的中间体的合成
US10343979B2 (en) 2014-11-18 2019-07-09 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
TWI540121B (zh) 2014-12-01 2016-07-01 臺灣永光化學工業股份有限公司 曲前列環素二乙醇胺之合成方法及新穎中間體
WO2016105538A1 (en) 2014-12-23 2016-06-30 Sandia Corporation Sandia National Laboratories Adjusting the ph of a pretreatment solution using carbon dioxide useful for integrating saccharification and fermentation
US20160243064A1 (en) * 2015-02-21 2016-08-25 Gavis Pharmaceuticals Novel oral pharmaceutical compositions of treprostinil
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US20190321290A1 (en) 2016-01-29 2019-10-24 Mannkind Corporation Composition and method for inhalation
KR20180133401A (ko) 2016-04-08 2018-12-14 이데미쓰 고산 가부시키가이샤 전기 화학 소자용 바인더
WO2018058124A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
CN119632930A (zh) 2019-04-29 2025-03-18 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
CN114616225A (zh) * 2019-08-23 2022-06-10 联合治疗公司 曲前列环素前药
IL296567A (en) 2020-04-17 2022-11-01 United Therapeutics Corp Terfostinil for use in the treatment of interstitial lung disease
AU2021289336B2 (en) 2020-06-09 2025-08-28 Mannkind Corporation Fumaryl diketopiperidine prodrugs of treprostinil

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504684A (ja) * 2016-01-29 2019-02-21 マンカインド コーポレイション 乾燥粉末吸入器
WO2019237028A1 (en) * 2018-06-07 2019-12-12 Mannkind Corporation Composition and method for inhalation

Also Published As

Publication number Publication date
US20220280430A1 (en) 2022-09-08
IL305510A (en) 2023-10-01
AU2022229367A1 (en) 2023-09-14
US12168071B2 (en) 2024-12-17
EP4301372A1 (en) 2024-01-10
US20250064743A1 (en) 2025-02-27
WO2022187352A1 (en) 2022-09-09
KR20240012354A (ko) 2024-01-29
CA3209987A1 (en) 2022-09-09
CN117479946A (zh) 2024-01-30

Similar Documents

Publication Publication Date Title
KR20240012354A (ko) (e)-3,6-비스[4-(n-카보닐-2-프로페닐)아미도부틸]-2,5-디케토피페라진(fdkp)을 추가로 포함하는, 트레프로스티닐 및 이의 프로드러그의 건조 분말 조성물
CN101265226B (zh) 化合物和释放前列环素类似物的方法
JP7603199B2 (ja) 重水素を含有する化合物
CZ281318B6 (cs) Monohydrát mometasonfuroátu, způsob přípravy této látky a přípravy lékových kompozic z ní
EP2319827A1 (en) Process for the production of polymorph form I of agomelatine
HK1052356A1 (en) Combretastatin a-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts; and mono-and di-amino acid ester salts
KR20140101869A (ko) 베툴린의 프로페노에이트 유도체
KR102849520B1 (ko) 트레프로스티닐 프로드러그로 질환을 치료하는 방법
EP0004494B1 (fr) Nouveaux dérivés de 1,3-dihydro 3-(1-(2-(2,3-dihydro 1,4-benzo-dioxin-2-yl)2-hydroxy éthyl)pipéridin-4-yl)2H-indol 2-one, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant
JP7410036B2 (ja) ベンゾジアゼピン誘導体塩酸塩および結晶形、その製造方法および用途
JP2008526835A (ja) シブトラミンのスルホン酸塩
US20160122274A1 (en) Salts of Sitagliptin, Process from the Preparation and Pharmaceutical Composition Therefore
CN117769541A (zh) 作为抗病毒剂的蛋白酶抑制剂
EP4652151A1 (en) Treprostinil analogs
EA045396B1 (ru) Соединения, содержащие дейтерий
CN114634484A (zh) 改进的奥希替尼或其盐的制备方法
EP3956287A1 (en) Prodrugs of monomethyl fumarate
HK40048606A (en) Compounds containing deuterium
HK40048606B (en) Compounds containing deuterium
US20010029306A1 (en) Aminohydroxylation of olefins in the presence of acetamide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260717